Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells

被引：0
|
作者：
Keller, Alexandra [1 ,2 ]
Peter, Barbara [1 ,2 ]
Zuber, Johannes [3 ]
Staber, Philipp Bernhard [2 ]
Bettelheim, Peter [4 ]
Valent, Peter [1 ,2 ]
Hadzijusufovic, Emir [1 ,2 ,5 ]
机构：
[1] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria
[2] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria
[3] Res Inst Mol Pathol IMP, Vienna, Austria
[4] Elisabethinen Hosp, Dept Med 1, Linz, Austria
[5] Univ Vet Med Vienna, Internal Med, Small Anim Clin, Dept Compan Anim & Horses, Vienna, Austria
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Pitpβ Loss Ameliorates Jak2 V617F-Induced Myeloproliferative Neoplasms (MPN) in Mice
    Vantsev, Nikita
    Zhao, Liang
    Abrams, Charles S.
    Tong, Wei
    BLOOD, 2024, 144 : 1753 - 1754
  • [12] NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant
    Shide, Kotaro
    Nakaya, Yohei
    Kameda, Takuro
    Shimoda, Haruko
    Hidaka, Tomonori
    Kubuki, Yoko
    Katayose, Keiko
    Matsunaga, Takuya
    Homan, Junko
    Kotera, Takashi
    Shibayama, Hiroshi
    Naito, Haruna
    Shimoda, Kazuya
    BLOOD, 2010, 116 (21) : 1671 - 1672
  • [13] THE EPIGENETIC READER BRD4 SERVES AS A NOVEL MARKER AND TARGET IN AGGRESSIVE SYSTEMIC MASTOCYTOSIS AND MAST CELL LEUKEMIA
    Wedeh, G.
    Cerny-Reiterer, S.
    Hadzijusufovic, E.
    Herrmann, H.
    Blatt, K.
    Eisenwort, G.
    Hoermann, G.
    Sperr, W. R.
    Muellauer, L.
    Vakoc, C. R.
    Bradner, J. E.
    Horny, H. P.
    Zuber, J.
    Arock, M.
    Valent, P.
    HAEMATOLOGICA, 2014, 99 : 514 - 515
  • [14] A novel regulating role of JAK2 FERM domain in hyperactivation of JAK2V617F
    Zhao, Lequn
    Huang, Lily
    CANCER RESEARCH, 2009, 69
  • [15] A Prolonged Low Level JAK2 V617F Is Significant In Clinically Suspicious Myeloproliferative Neoplasms (MPN)
    Vail, E.
    Chevarie-Davis, M.
    Riley, C.
    Lopategui, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 957 - 958
  • [16] Low Level JAK2 V617F Is Significant in Confirming a Clinical Suspicion of Myeloproliferative Neoplasms (MPN)
    Chevarie-Davis, M.
    Riley, A. C.
    Lopategui, J.
    MODERN PATHOLOGY, 2014, 27 : 342A - 342A
  • [17] MOLECULAR STUDY OF CALR GENE: MYELOPROLIFERATIVE NEOPLASMS (MPN) WITH NEGATIVE PHILADELPHIA AND JAK2/V617F
    Culurgioni, F.
    Musiu, C.
    Uda, S.
    Benziane, A.
    Pettinau, M.
    Usala, E.
    Cabras, M. G.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [18] Low Level JAK2 V617F Is Significant in Confirming a Clinical Suspicion of Myeloproliferative Neoplasms (MPN)
    Chevarie-Davis, M.
    Riley, A. C.
    Lopategui, J.
    LABORATORY INVESTIGATION, 2014, 94 : 342A - 342A
  • [19] MPN患者JAK2基因V617F点突变的检测及意义
    张树鹏
    赖仁胜
    杜益群
    谢玲
    吴晓斌
    郑燕影
    陈劼
    赵苏苏
    李惠
    山东医药, 2011, 51 (30) : 105 - 106
  • [20] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
    Holmstrom, M. O.
    Hjortso, M. D.
    Ahmad, S. M.
    Met, O.
    Martinenaite, E.
    Riley, C.
    Straten, P.
    Svane, I. M.
    Hasselbalch, H. C.
    Andersen, M. H.
    LEUKEMIA, 2017, 31 (02) : 495 - 498
12345